Integrins: Signaling, disease, and therapy

References

• Abdollahi A, Griggs D W, Zieher H, Roth A, Lipson K E, Saffrich R, Grone H J, Hallahan D E, Reisfeld R A, Debus J, Niethammer A G, Huber P E. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clinical Cancer Research 2005; 11: 6270–6279
   PubMed Web of Science ®Google Scholar
• Aggarwal B B, Bhardwaj A, Aggarwal R S, Seeram N P, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Research 2004; 24: 2783–2840
   PubMed Web of Science ®Google Scholar
• Albert J M, Cao C, Geng L, Leavitt L, Hallahan D E, Lu B. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. International Journal of Radiation Oncology, Biology, Physics 2006; 65: 1536–1543
   PubMed Web of Science ®Google Scholar
• Allman R, Cowburn P, Mason M. In vitro and in vivo effects of a cyclic peptide with affinity for the alpha(nu)beta3 integrin in human melanoma cells. European Journal of Cancer 2000; 36: 410–422
   PubMed Web of Science ®Google Scholar
• Almeida E A, Ilic D, Han Q, Hauck C R, Jin F, Kawakatsu H, Schlaepfer D D, Damsky C H. Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase. Journal of Cell Biology 2000; 149: 741–754
   PubMed Web of Science ®Google Scholar
• Assoian R K, Schwartz M A. Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Current Opinion in Genetics & Development 2001; 11: 48–53
   PubMed Web of Science ®Google Scholar
• Badger A M, Blake S, Kapadia R, Sarkar S, Levin J, Swift B A, Hoffman S J, Stroup G B, Miller W H, Gowen M, Lark M W. Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis & Rheumatism 2001; 44: 128–137
   PubMed Web of Science ®Google Scholar
• Batt D G, Petraitis J J, Houghton G C, Modi D P, Cain G A, Corjay M H, Mousa S A, Bouchard P J, Forsythe M S, Harlow P P, Barbera F A, Spitz S M, Wexler R R, Jadhav P K. Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3). Journal of Medicinal Chemistry 2000; 43: 41–58
   PubMed Web of Science ®Google Scholar
• Benaud C M, Dickson R B. Regulation of the expression of c-Myc by beta1 integrins in epithelial cells. Oncogene 2001; 20: 759–768
   PubMed Web of Science ®Google Scholar
• Bennett J S. Novel platelet inhibitors. Annual Review of Medicine 2001; 52: 161–184
   PubMed Web of Science ®Google Scholar
• Bokel C, Brown N H. Integrins in development: Moving on, responding to, and sticking to the extracellular matrix. Developmental Cell 2002; 3: 311–321
   PubMed Web of Science ®Google Scholar
• Borradori L, Sonnenberg A. Structure and function of hemidesmosomes: more than simple adhesion complexes. Journal of Investigative Dermatology 1999; 112: 411–418
   PubMed Web of Science ®Google Scholar
• Bouvard D, Brakebusch C, Gustafsson E, Aszodi A, Bengtsson T, Berna A, Fassler R. Functional consequences of integrin gene mutations in mice. Circulation Research 2001; 89: 211–223
   PubMed Web of Science ®Google Scholar
• Brooks P C, Clark R A, Cheresh D A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994a; 264: 569–571
   PubMed Web of Science ®Google Scholar
• Brooks P C, Montgomery A M, Rosenfeld M, Reisfeld R A, Hu T, Klier G, Cheresh D A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994b; 79: 1157–1164
   PubMed Web of Science ®Google Scholar
• Brooks P C, Stromblad S, Klemke R, Visscher D, Sarkar F H, Cheresh D A. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. Journal of Clinical Investigation 1995; 96: 1815–1822
   PubMed Web of Science ®Google Scholar
• Burridge K, Chrzanowska-Wodnicka M. Focal adhesions, contractility, and signaling. Annual Review of Cell and Developmental Biology 1996; 12: 463–518
   PubMed Web of Science ®Google Scholar
• Cai W, Chen X. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anti-Cancer Agents in Medicinal Chemistry 2006; 6: 407–428
   PubMedGoogle Scholar
• Carter P. Improving the efficacy of antibody-based cancer therapies. Nature Reviews Cancer 2001; 1: 118–129
   PubMed Web of Science ®Google Scholar
• Chen Q, Lin T H, Der C J, Juliano R L. Integrin-mediated activation of MEK and mitogen-activated protein kinase is independent of Ras [corrected]. Journal of Biological Chemistry 1996; 271: 18122–18127
   PubMed Web of Science ®Google Scholar
• Cheresh D A. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proceedings of the National Academy of Sciences USA 1987; 84: 6471–6475
   PubMed Web of Science ®Google Scholar
• Clark E A, Trikha M, Markland F S, Brugge J S. Structurally distinct disintegrins contortrostatin and multisquamatin differentially regulate platelet tyrosine phosphorylation. Journal of Biological Chemistry 1994; 269: 21940–21943
   PubMed Web of Science ®Google Scholar
• Colomer R. Gemcitabine and paclitaxel in metastatic breast cancer: A review. Oncology (Williston. Park) 2004; 18: 8–12
   PubMedGoogle Scholar
• Cordes N. Integrin-mediated cell-matrix interactions for prosurvival and antiapoptotic signaling after genotoxic injury. Cancer Letters 2006; 242: 11–19
   PubMed Web of Science ®Google Scholar
• Cortijo J, Sanz M J, Iranzo A, Montesinos J L, Nabah Y N, Alfon J, Gomez L A, Merlos M, Morcillo E J. A small molecule, orally active, alpha4beta1/alpha4beta7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats. British Journal of Pharmacology 2006; 147: 661–670
   PubMed Web of Science ®Google Scholar
• Danen E H, Yamada K M. Fibronectin, integrins, and growth control. Journal of Cellular Physiology 2001; 189: 1–13
   PubMed Web of Science ®Google Scholar
• De Arcangelis A, Georges-Labouesse E. Integrin and ECM functions: Roles in vertebrate development. Trends in Genetics 2000; 16: 389–395
   PubMed Web of Science ®Google Scholar
• Dechantsreiter M A, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A, Goodman S L, Kessler H. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. Journal of Medicinal Chemistry 1999; 42: 3033–3040
   PubMed Web of Science ®Google Scholar
• Edwards G M, Wilford F H, Liu X, Hennighausen L, Djiane J, Streuli C H. Regulation of mammary differentiation by extracellular matrix involves protein-tyrosine phosphatases. Journal of Biological Chemistry 1998; 273: 9495–9500
   PubMed Web of Science ®Google Scholar
• Engleman V W, Nickols G A, Ross F P, Horton M A, Griggs D W, Settle S L, Ruminski P G, Teitelbaum S L. A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. Journal of Clinical Investigation 1997; 99: 2284–2292
   PubMed Web of Science ®Google Scholar
• Evans R D, Perkins V C, Henry A, Stephens P E, Robinson M K, Watt F M. A tumor-associated beta 1 integrin mutation that abrogates epithelial differentiation control. Journal of Cell Biology 2003; 160: 589–596
   PubMed Web of Science ®Google Scholar
• Faham S, Linhardt R J, Rees D C. Diversity does make a difference: fibroblast growth factor-heparin interactions. Current Opinion in Structural Biology 1998; 8: 578–586
   PubMed Web of Science ®Google Scholar
• Fassler R, Rohwedel J, Maltsev V, Bloch W, Lentini S, Guan K, Gullberg D, Hescheler J, Addicks K, Wobus A M. Differentiation and integrity of cardiac muscle cells are impaired in the absence of beta 1 integrin. Journal of Cell Science 1996; 109(Pt 13)2989–2999
   PubMedGoogle Scholar
• Feagan B G, Greenberg G R, Wild G, Fedorak R N, Pare P, McDonald J W, Dube R, Cohen A, Steinhart A H, Landau S, Aguzzi R A, Fox I H, Vandervoort M K. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine 2005; 352: 2499–2507
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 1971; 285: 1182–1186
   PubMed Web of Science ®Google Scholar
• Friedlander M, Brooks P C, Shaffer R W, Kincaid C M, Varner J A, Cheresh D A. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270: 1500–1502
   PubMed Web of Science ®Google Scholar
• Frisch S M, Screaton R A. Anoikis mechanisms. Current Opinion in Cell Biology 2001; 13: 555–562
   PubMed Web of Science ®Google Scholar
• Gardner J M, Hynes R O. Interaction of fibronectin with its receptor on platelets. Cell 1985; 42: 439–448
   PubMed Web of Science ®Google Scholar
• Geiger B, Bershadsky A, Pankov R, Yamada K M. Transmembrane crosstalk between the extracellular matrix – cytoskeleton crosstalk. Nature Reviews Molecular Cell Biology 2001; 2: 793–805
   PubMed Web of Science ®Google Scholar
• Ghosh S, Goldin E, Gordon F H, Malchow H A, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S. Natalizumab for active Crohn's disease. New England Journal of Medicine 2003; 348: 24–32
   PubMed Web of Science ®Google Scholar
• Giancotti F G, Ruoslahti E. Integrin signaling. Science 1999; 285: 1028–1032
   PubMed Web of Science ®Google Scholar
• Giavazzi R, Nicoletti M I. Small molecules in anti-angiogenic therapy. Current Opinion in Investigational Drugs 2002; 3: 482–491
   PubMedGoogle Scholar
• Gilcrease M Z. Integrin signaling in epithelial cells. Cancer Letters 2007; 247: 1–25
   PubMed Web of Science ®Google Scholar
• Goodman S L, Holzemann G, Sulyok G A, Kessler H. Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. Journal of Medicinal Chemistry 2002; 45: 1045–1051
   PubMed Web of Science ®Google Scholar
• Gould R J, Polokoff M A, Friedman P A, Huang T F, Holt J C, Cook J J, Niewiarowski S. Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proceedings of the Society for Experimental Biology & Medicine 1990; 195: 168–171
   PubMed Web of Science ®Google Scholar
• Guo W, Giancotti F G. Integrin signalling during tumour progression. Nature Reviews Molecular Cell Biology 2004; 5: 816–826
   PubMed Web of Science ®Google Scholar
• Hartman G D, Duggan M E. alpha(v)beta(3) Integrin antagonists as inhibitors of bone resorption. Expert Opinion on Investigational Drugs 2000; 9: 1281–1291
   PubMed Web of Science ®Google Scholar
• Haskill S, Johnson C, Eierman D, Becker S, Warren K. Adherence induces selective mRNA expression of monocyte mediators and proto-oncogenes. Journal of Immunology 1988; 140: 1690–1694
   PubMed Web of Science ®Google Scholar
• Hodivala-Dilke K M, McHugh K P, Tsakiris D A, Rayburn H, Crowley D, Ullman-Cullere M, Ross F P, Coller B S, Teitelbaum S, Hynes R O. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. Journal of Clinical Investigation 1999; 103: 229–238
   PubMed Web of Science ®Google Scholar
• Howe A K, Aplin A E, Juliano R L. Anchorage-dependent ERK signaling – mechanisms and consequences. Current Opinion in Genetics & Development 2002; 12: 30–35
   PubMed Web of Science ®Google Scholar
• Huang T F. What have snakes taught us about integrins?. Cellular & Molecular Life Sciences 1998; 54: 527–540
   PubMed Web of Science ®Google Scholar
• Hynes R O. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673–687
   PubMed Web of Science ®Google Scholar
• Jain R K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58–62
   PubMed Web of Science ®Google Scholar
• Kerr J S, Slee A M, Mousa S A. Small molecule alpha(v) integrin antagonists: novel anticancer agents. Expert Opinion on Investigational Drugs 2000; 9: 1271–1279
   PubMed Web of Science ®Google Scholar
• Kim S, Bell K, Mousa S A, Varner J A. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. American Journal of Pathology 2000; 156: 1345–1362
   PubMed Web of Science ®Google Scholar
• Lakkakorpi P T, Helfrich M H, Horton M A, Vaananen H K. Spatial organization of microfilaments and vitronectin receptor, alpha v beta 3, in osteoclasts. A study using confocal laser scanning microscopy. Journal of Cell Science 1993; 104(Pt 3)663–670
   PubMedGoogle Scholar
• Lebwohl M, Tyring S K, Hamilton T K, Toth D, Glazer S, Tawfik N H, Walicke P, Dummer W, Wang X, Garovoy M R, Pariser D. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. New England Journal of Medicine 2003; 349: 2004–2013
   PubMed Web of Science ®Google Scholar
• Lelievre S A, Weaver V M, Nickerson J A, Larabell C A, Bhaumik A, Petersen O W, Bissell M J. Tissue phenotype depends on reciprocal interactions between the extracellular matrix and the structural organization of the nucleus. Proceedings of the National Academy of Sciences USA 1998; 95: 14711–14716
   PubMed Web of Science ®Google Scholar
• Li M L, Aggeler J, Farson D A, Hatier C, Hassell J, Bissell M J. Influence of a reconstituted basement membrane and its components on casein gene expression and secretion in mouse mammary epithelial cells. Proceedings of the National Academy of Sciences USA 1987; 84: 136–140
   PubMed Web of Science ®Google Scholar
• Liddington R C, Ginsberg M H. Integrin activation takes shape. Journal of Cell Biology 2002; 158: 833–839
   PubMed Web of Science ®Google Scholar
• Lin H Y, Lansing L, Merillon J M, Davis F B, Tang H Y, Shih A, Vitrac X, Krisa S, Keating T, Cao H J, Bergh J, Quackenbush S, Davis P J. Integrin alphaVbeta3 contains a receptor site for resveratrol. FASEB Journal 2006; 20: 1742–1744
   PubMed Web of Science ®Google Scholar
• Liu F, Craft R M, Morris S A, Carroll R C. Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker. Expert Opinion on Investigational Drugs 2000; 9: 2673–2687
   PubMed Web of Science ®Google Scholar
• Livant D L, Brabec R K, Pienta K J, Allen D L, Kurachi K, Markwart S, Upadhyaya A. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Research 2000; 60: 309–320
   PubMed Web of Science ®Google Scholar
• Lode H N, Moehler T, Xiang R, Jonczyk A, Gillies S D, Cheresh D A, Reisfeld R A. Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proceedings of the National Academy of Sciences USA 1999; 96: 1591–1596
   PubMed Web of Science ®Google Scholar
• Maniotis A J, Chen C S, Ingber D E. Demonstration of mechanical connections between integrins, cytoskeletal filaments, and nucleoplasm that stabilize nuclear structure. Proceedings of the National Academy of Sciences USA 1997; 94: 849–854
   PubMed Web of Science ®Google Scholar
• McLane M A, Sanchez E E, Wong A, Paquette-Straub C, Perez J C. Disintegrins. Current Drug Targets – Cardiovascular & Haematological Disorders 2004; 4: 327–355
   PubMedGoogle Scholar
• Menko A S, Boettiger D. Occupation of the extracellular matrix receptor, integrin, is a control point for myogenic differentiation. Cell 1987; 51: 51–57
   PubMed Web of Science ®Google Scholar
• Mikecz K. Vitaxin applied molecular evolution. Current Opinion in Investigational Drugs 2000; 1: 199–203
   PubMedGoogle Scholar
• Miller D H, Khan O A, Sheremata W A, Blumhardt L D, Rice G P, Libonati M A, Willmer-Hulme A J, Dalton C M, Miszkiel K A, O'Connor P W. A controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine 2003; 348: 15–23
   PubMed Web of Science ®Google Scholar
• Mizejewski G J. Role of integrins in cancer: survey of expression patterns. Proceedings of the Society for Experimental Biology & Medicine 1999; 222: 124–138
   PubMed Web of Science ®Google Scholar
• O'Reilly M S, Boehm T, Shing Y, Fukai N, Vasios G, Lane W S, Flynn E, Birkhead J R, Olsen B R, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–285
   PubMed Web of Science ®Google Scholar
• Pierschbacher M D, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984; 309: 30–33
   PubMed Web of Science ®Google Scholar
• Pitts W J, Wityak J, Smallheer J M, Tobin A E, Jetter J W, Buynitsky J S, Harlow P P, Solomon K A, Corjay M H, Mousa S A, Wexler R R, Jadhav P K. Isoxazolines as potent antagonists of the integrin alpha(v)beta(3). Journal of Medicinal Chemistry 2000; 43: 27–40
   PubMed Web of Science ®Google Scholar
• Plow E F, Pierschbacher M D, Ruoslahti E, Marguerie G A, Ginsberg M H. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proceedings of the National Academy of Sciences USA 1985; 82: 8057–8061
   PubMed Web of Science ®Google Scholar
• Posey J A, Khazaeli M B, DelGrosso A, Saleh M N, Lin C Y, Huse W, LoBuglio A F. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biotherapy & Radiopharmaceuticals 2001; 16: 125–132
   PubMed Web of Science ®Google Scholar
• Rader C, Popkov M, Neves J A, Barbas C F, III. Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. FASEB Journal 2002; 16: 2000–2002
   PubMed Web of Science ®Google Scholar
• Raguse J D, Gath H J, Bier J, Riess H, Oettle H. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncology 2004; 40: 228–230
   PubMed Web of Science ®Google Scholar
• Reinmuth N, Liu W, Ahmad S A, Fan F, Stoeltzing O, Parikh A A, Bucana C D, Gallick G E, Nickols M A, Westlin W F, Ellis L M. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Research 2003; 63: 2079–2087
   PubMed Web of Science ®Google Scholar
• Renshaw M W, Ren X D, Schwartz M A. Growth factor activation of MAP kinase requires cell adhesion. EMBO Journal 1997; 16: 5592–5599
   PubMed Web of Science ®Google Scholar
• Rohwedel J, Guan K, Zuschratter W, Jin S, Hnert-Hilger G, Furst D, Fassler R, Wobus A M. Loss of beta1 integrin function results in a retardation of myogenic, but an acceleration of neuronal, differentiation of embryonic stem cells in vitro. Developmental Biology 1998; 201: 167–184
   PubMed Web of Science ®Google Scholar
• Ruoslahti E. RGD and other recognition sequences for integrins. Annual Review of Cell & Developmental Biology 1996; 12: 697–715
   PubMed Web of Science ®Google Scholar
• Schlaepfer D D, Hunter T. Integrin signalling and tyrosine phosphorylation: Just the FAKs?. Trends in Cell Biology 1998; 8: 151–157
   PubMed Web of Science ®Google Scholar
• Shattil S J. Integrins and Src: Dynamic duo of adhesion signaling. Trends in Cell Biology 2005; 15: 399–403
   PubMed Web of Science ®Google Scholar
• Shi C, Simon D I. Integrin signals, transcription factors, and monocyte differentiation. Trends in Cardiovascular Medicine 2006; 16: 146–152
   PubMed Web of Science ®Google Scholar
• Shimaoka M, Springer T A. Therapeutic antagonists and conformational regulation of integrin function. Nature Reviews Drug Discovery 2003; 2: 703–716
   PubMed Web of Science ®Google Scholar
• Sircar I, Gudmundsson K S, Martin R, Liang J, Nomura S, Jayakumar H, Teegarden B R, Nowlin D M, Cardarelli P M, Mah J R, Connell S, Griffith R C, Lazarides E. Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: Discovery of TR-14035, a dual alpha(4)beta(7)/alpha(4)beta(1) integrin antagonist. Bioorganic & Medicinal Chemistry 2002; 10: 2051–2066
   PubMed Web of Science ®Google Scholar
• Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry G C, Parikh A A, McCarty M F, Bucana C D, Mazar A P, Ellis L M. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. International Journal of Cancer 2003; 104: 496–503
   PubMed Web of Science ®Google Scholar
• Stupack D G, Puente X S, Boutsaboualoy S, Storgard C M, Cheresh D A. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. Journal of Cell Biology 2001; 155: 459–470
   PubMed Web of Science ®Google Scholar
• Swenson S, Costa F, Ernst W, Fujii G, Markland F S. Contortrostatin, a snake venom disintegrin with anti-angiogenic and anti-tumor activity. Pathophysiology of Haemostasis and Thrombosis 2005; 34: 169–176
   PubMedGoogle Scholar
• Taga T, Suzuki A, Gonzalez-Gomez I, Gilles F H, Stins M, Shimada H, Barsky L, Weinberg K I, Laug W E. alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. International Journal of Cancer 2002; 98: 690–697
   PubMed Web of Science ®Google Scholar
• Teicher B A. A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics – >mechanism(s) of interaction). Cancer and Metastasis Reviews 1996; 15: 247–272
   PubMed Web of Science ®Google Scholar
• Trikha M, Rote W E, Manley P J, Lucchesi B R, Markland F S. Purification and characterization of platelet aggregation inhibitors from snake venoms. Thrombosis Research 1994; 73: 39–52
   PubMed Web of Science ®Google Scholar
• Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E, Nakada M T. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Research 2002; 62: 2824–2833
   PubMed Web of Science ®Google Scholar
• Vachon P H, Xu H, Liu L, Loechel F, Hayashi Y, Arahata K, Reed J C, Wewer U M, Engvall E. Integrins (alpha7beta1) in muscle function and survival. Disrupted expression in merosin-deficient congenital muscular dystrophy. Journal of Clinical Investigation 1997; 100: 1870–1881
   PubMed Web of Science ®Google Scholar
• van der Flier A, Sonnenberg A. Function and interactions of integrins. Cell & Tissue Research 2001; 305: 285–298
   PubMed Web of Science ®Google Scholar
• Varner J A, Emerson D A, Juliano R L. Integrin alpha 5 beta 1 expression negatively regulates cell growth: Reversal by attachment to fibronectin. Molecular Biology of the Cell 1995; 6: 725–740
   PubMed Web of Science ®Google Scholar
• Watt F M. Role of integrins in regulating epidermal adhesion, growth and differentiation. EMBO Journal 2002; 21: 3919–3926
   PubMed Web of Science ®Google Scholar
• Weaver V M, Lelievre S, Lakins J N, Chrenek M A, Jones J C, Giancotti F, Werb Z, Bissell M J. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002; 2: 205–216
   PubMed Web of Science ®Google Scholar
• Wu A M, Senter P D. Arming antibodies: Prospects and challenges for immunoconjugates. Nature Biotechnology 2005; 23: 1137–1146
   PubMed Web of Science ®Google Scholar
• Yamada K M, Even-Ram S. Integrin regulation of growth factor receptors. Nature Cell Biology 2002; 4: E75–76
   PubMed Web of Science ®Google Scholar